Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

STADA Arzneimittel AG M&A Activity 2001

Nov 7, 2001

412_rns_2001-11-07_7c8f2c0f-737a-4f09-b849-d5ca055b0d8a.html

M&A Activity

Open in viewer

Opens in your device viewer

News Details

Ad-hoc | 7 November 2001 08:17

STADA Arzneimittel AG english

STADA acquires US generics business Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– STADA acquires US generics business STADA Arzneimittel AG, based in Bad Vilbel, Germany, is to acquire full ownership of the business operations of the generic supplier MOVA Laboratories Inc., in Cran-bury, New Jersey, USA, as of January 1, 2002. STADA reached this agreement with the parent company of MOVA Laboratories, MOVA Pharmaceutical Co., Puerto Rico. The acquisition will give STADA ownership over MOVAs pharmaceutical product approvals as well as its sales in the USA, which in the current year 2001 are likely to amount to USD 26 million. The product range comprises 15 generic drugs and one branded product. In addition, STADA will also be acquiring from MOVA 5 development projects for US generic approval, 12 further US generic approvals which are currently not marketed, as well as all the documents and agreements with customers and suppliers which are necessary for the continued operation of the business. With this acquisition STADA is acquiring a lean marketing and distribution unit for generic drugs and inexpensive branded products in the USA. More acquisitions of approvals and products are planned. The company STADA Arzneimittel AG, which is listed on the German mid-cap index MDAX, is one of Europes leading suppliers of generic drugs. Sales in 2001 are forecast to exceed DM 1 billion. With the acquisition of the business operations of MOVA Laboratories, STADA is now represented in the worlds largest national generics market, the US market. For further information please contact: STADA Arzneimittel AG / Corporate Communications / D-61118 Bad Vilbel Phone: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 / E-mail: [email protected] Or visit our website at http://www.stada.de end of ad-hoc-announcement (c)DGAP 07.11.2001 ——————————————————————————– WKN: 725180; Index: MDAX Listed: Amtlicher Handel in Frankfurt und Düsseldorf; Freiverkehr in Berlin, Bremen, Hamburg, München und Stuttgart 070817 Nov 01